PLATINO, estudo de seguimento de nove anos sobre DPOC na cidade de São Paulo: o problema do subdiagnóstico by Moreira, Graciane Laender et al.
J Bras Pneumol. 2013;40(1):30-37
PLATINO, a nine-year follow-up study of COPD in the city of 
São Paulo, Brazil: the problem of underdiagnosis*
PLATINO, estudo de seguimento de nove anos sobre DPOC na  
cidade de São Paulo: o problema do subdiagnóstico
Graciane Laender Moreira, Beatriz Martins Manzano, Mariana Rodrigues Gazzotti, 
Oliver Augusto Nascimento, Rogelio Perez-Padilla, Ana Maria Baptista Menezes, 
José Roberto Jardim
Abstract
Objective: To determine the underdiagnosis rate in new COPD cases at the end of a nine-year follow-up 
period—in the study designated “Projeto Latino-Americano de Investigação em Obstrução Pulmonar” (PLATINO, 
Latin-American Pulmonary Obstruction Investigation Project)—and compare that with the underdiagnosis rate 
during the initial phase of the study, as well as to identify the clinical features exhibited by the subjects who 
were not diagnosed until the end of the follow-up phase. Methods: The study population comprised the 1,000 
residents of the city of São Paulo, Brazil, who took part in the PLATINO study. Of those, 613 participated in the 
follow-up phase, during which the subjects were assessed with the same instruments and equipment employed 
in the initial phase of the study. We used the chi-square test or the independent sample t-test to analyze the 
underdiagnosis rate and to identify the characteristics of the subjects who were not diagnosed until the end 
of the follow-up phase. Results: The underdiagnosis rate for new COPD cases at the end of the nine-year 
follow-up period was 70.0%. The underdiagnosis rate during the follow-up phase was 17.5% lower than that 
reported for the initial phase of the study. The subjects who were not diagnosed until the end of the follow-up 
phase presented with fewer respiratory symptoms, better pulmonary function, and less severe disease than did 
those previously diagnosed with COPD. Conclusions: The underdiagnosis rate for new COPD cases was lower 
in the follow-up phase of the study than in the initial phase. The subjects who were not diagnosed until the 
end of the follow-up phase of the PLATINO study presented with the same clinical profile as did those who 
were not diagnosed in the initial phase. These findings underscore the need for spirometry in order to confirm 
the diagnosis of COPD and provide early intervention.
Keywords: Pulmonary disease, chronic obstructive/diagnosis; Pulmonary disease, chronic obstructive/
epidemiology; Spirometry.
Resumo
Objetivo: Determinar a taxa de subdiagnóstico em novos casos de DPOC em uma amostra de pacientes após 
nove anos de seguimento do estudo “Projeto Latino-Americano de Investigação em Obstrução Pulmonar” 
(PLATINO) e compará-la à taxa de subdiagnóstico obtida na fase inicial do estudo, assim como identificar as 
características clínicas dos indivíduos subdiagnosticados na fase de seguimento. Métodos: A população desse 
estudo foi composta por 1.000 residentes na cidade de São Paulo que fizeram parte do estudo PLATINO. Desses, 
613 indivíduos participaram da fase de seguimento. Os indivíduos foram avaliados utilizando-se os mesmos 
instrumentos e equipamentos na fase inicial do estudo. O teste do qui-quadrado ou o teste t para amostras 
independentes foi utilizado para analisar a taxa de subdiagnóstico e identificar as características dos indivíduos 
subdiagnosticados durante a fase de seguimento. Resultados: A taxa de subdiagnóstico para novos casos da DPOC 
após nove anos de acompanhamento foi de 70,0%. A taxa de subdiagnóstico na fase de seguimento foi 17,5% 
menor que a da fase inicial do estudo. Os indivíduos subdiagnosticados na fase de seguimento apresentavam 
poucos sintomas respiratórios, função pulmonar mais preservada e menor gravidade da doença do que aqueles 
previamente diagnosticados com DPOC. Conclusões: A taxa de subdiagnóstico na fase de seguimento foi menor 
que a da fase inicial do estudo. Os indivíduos subdiagnosticados na fase de seguimento do estudo PLATINO 
apresentavam o mesmo perfil clínico daqueles subdiagnosticados na fase inicial. Esses achados reforçam a 
necessidade da utilização da espirometria para o diagnóstico de DPOC e possibilitar a intervenção precoce. 
Descritores: Doença pulmonar obstrutiva crônica/diagnóstico; Doença pulmonar obstrutiva crônica/
epidemiologia; Espirometria.
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Methods
The present study population comprised the 
same subjects who originally took part in the 
initial phase of the PLATINO study in the city of 
São Paulo, Brazil (n = 1,000). Of those, a total 
of 613 subjects participated in this follow-up 
phase. The present study was approved by the 
Research Ethics Committee of the Universidade 
Federal de São Paulo (UNIFESP, Federal University 
of São Paulo) Hospital São Paulo (Ruling no. 
04234/10), and, after being informed of the 
study and procedures, all subjects who agreed 
to participate gave written informed consent.
The information on the sampling process 
for the initial phase of the PLATINO study has 
been described in a previous study.(3)
All houses in which the subjects were 
interviewed in the initial phase of the PLATINO 
study were visited. The initial contact was made 
by one of four screeners, who confirmed whether 
the subjects still lived at those addresses, checked 
their telephone number, and informed them of 
the interviewers’ visit.
With regard to the subjects who did not live 
in the same house (as that of the initial phase 
of the PLATINO study) anymore, the screeners 
sought to determine their whereabouts through 
information from neighbors or through inquiries 
in the neighborhood businesses. The names of 
those whose whereabouts was unknown were 
looked up in the registry of deaths within the 
state of São Paulo and other Brazilian states. All 
data obtained by the screeners were sent to the 
coordinating body responsible for organizing the 
files for the subsequent scheduling of interviews.
Before performing the field evaluation, all 
interviewers (14 physiotherapy undergraduates 
and physiotherapists) attended a training course, 
which included administering the questionnaire 
and performing spirometry, taught by the São 
Paulo team. Once the coordinating body was 
assured that the interviewers were qualified 
to perform the evaluations, a pilot study was 
conducted to clarify issues that could arise during 
the fieldwork, thereby ending the training phase 
for the interviewers. Once the pilot study was 
completed, the scheduling of visits (which was 
performed by the supervisors) actually began, 
and the respondents were subsequently visited 
by two interviewers.
At the respondent’s house, the researchers first 
required written informed consent from the subject 
Introduction
The study designated Projeto Latino-
Americano de Investigação em Obstrução 
Pulmonar (PLATINO, Latin-American Pulmonary 
Obstruction Investigation Project) is a population-
based epidemiological study in which the main 
objective was to investigate the prevalence of 
COPD in five major cities in Latin America.(1)
In the city of São Paulo, Brazil, the prevalence 
of COPD was 15.8%.(2) Despite such high prevalence, 
a small proportion of subjects had actually been 
diagnosed with the disease. Only 12.5% of the 
patients with spirometry-diagnosed COPD already 
had an established clinical diagnosis of COPD, 
although a significant number of patients had 
well-defined symptoms of the disease.(3) The main 
factor related to underdiagnosis is the infrequent 
use of spirometry as a diagnostic tool.(4)
Misdiagnosis or undiagnosis makes it unlikely 
that effective interventions will occur. This becomes 
evident when one examines again the findings 
from the PLATINO study, in which 83.3% of 
the subjects diagnosed with COPD in the city 
of São Paulo were found not to receive any 
pharmacological treatment. In addition, 47.3% 
were not advised to stop smoking, and 72.4% 
did not receive the flu vaccine.(5)
These findings show that COPD is an 
underdiagnosed and undertreated disease, which 
can have serious consequences for patients, such 
as higher morbidity and mortality, and can result 
in substantial economic impact on the health care 
system. Therefore, accurate, up-to-date information 
on COPD underdiagnosis is important in order 
to assist authorities and health professionals 
in implementing strategies for identifying and 
helping subjects with COPD, regardless of their 
degree of disease severity.(6)
The objective of the present study was to 
determine the underdiagnosis rate in new COPD 
cases at the end of a nine-year follow-up period 
and compare that with the underdiagnosis rate in 
prevalent COPD cases during the initial phase of 
the PLATINO study, as well as to determine the 
anthropometric characteristics, clinical features, 
and history of exposure to COPD risk factors of 
the subjects who went undiagnosed until the 
end of the follow-up phase of the PLATINO 
study, conducted in the city of São Paulo, Brazil, 
and compare them with those of the subjects 
previously diagnosed with COPD.
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ever told you that you have chronic obstructive 
pulmonary disease (COPD)?”
A case of underdiagnosis was defined as that 
in which the subject answered “no” to the first 
three questions and had a post-bronchodilator 
FEV1/FVC ratio < 0.7.
The data collected during the follow-up phase 
of the PLATINO study were added to the original 
database of the initial phase of the study, which 
was conducted in 2003, in the city of São Paulo, 
Brazil. Data analysis was performed with the 
Statistical Package for the Social Sciences, version 
17.0 (SPSS Inc., Chicago, IL, USA), and the level 
of statistical significance was set at p < 0.05.
The underdiagnosis rate in new cases at the 
end of the nine-year follow-up period was assessed 
with the chi-square test, which was also used to 
compare the characteristics of the subjects who 
went undiagnosed until the end of the follow-up 
phase of the PLATINO study with those of the 
subjects with a prior diagnosis of COPD, when 
variables were categorical. For numerical variables, 
we used the t-test for independent samples. 
The characteristics investigated were as follows: 
gender; age; level of education; nutritional status; 
pulmonary function; disease severity; symptoms; 
quality of life; exposure to COPD risk factors 
(burning wood/dung or charcoal; smoking; and 
history of respiratory infections in childhood).
For continuous variables, the results are 
expressed as mean and standard deviation. 
Categorical variables are expressed as absolute 
values and as percentages, representing the 
number of cases in each category.
Results
The data regarding the follow-up phase of 
the PLATINO study in the city of São Paulo, 
Brazil, are shown in Figure 1.
Table 1 shows the rates of underdiagnosis 
and prior diagnosis of COPD in new (incident) 
COPD cases and in all COPD cases during the 
follow-up phase of the PLATINO study in the 
city of São Paulo, Brazil. It can be seen that 
70.0% of the incident COPD cases and 62.3% 
of all COPD cases during this follow-up phase 
had airflow obstruction but had no physician-
diagnosed COPD.
The underdiagnosis rates found for incident 
COPD cases (follow-up phase of the PLATINO 
study) and for prevalent COPD cases (initial phase 
of the PLATINO study), all of which were classified 
and, if the subject agreed to participate in the 
study, they proceeded to data collection, according 
to the following sequence: anthropometric 
assessment; completion of the questionnaire with 
exclusion criteria for participation in spirometry(1); 
pre-bronchodilator spirometry; administration of 
a portion of the main questionnaire (in the first 
15 minutes after bronchodilator administration); 
post-bronchodilator spirometry; administration 
of the remainder of the main questionnaire.
The main questionnaire administered in this 
follow-up phase was the same as that used in 
the initial phase of the PLATINO study(1) (a 
combined version of the American Thoracic 
Society-Division of Lung Disease questionnaire,(7) 
the European Community Respiratory Health 
Survey II questionnaire,(8) and the Lung Health 
Study questionnaire) added with new questions 
on smoking, diagnosis, asthma, physical activity, 
sleep, and depression.
The diagnosis of COPD was confirmed by 
spirometry, which was performed before and 
after bronchodilator use, in accordance with the 
American Thoracic Society/European Respiratory 
Society guidelines.(9) Spirometric measurements 
were taken with a portable battery-powered 
spirometer and an ultrasound system (EasyOne™; 
Medical Technologies, Chelmsparad, MA, USA and 
NDD Medizintechnik AG, Zurich, Switzerland), 
identical to those used in the initial phase of 
the PLATINO study. Participants performed up 
to 15 forced expiratory maneuvers in order to 
achieve quality-A level, i.e., three acceptable 
maneuvers yielding the highest FEV1 and FVC 
values, without exceeding a difference of 150 
L. Subsequently, an inhaled bronchodilator 
(albuterol, 200 μg) was administered, with the 
use of a 500-mL spacer, and, after 15 minutes, 
the test was repeated. All spirometric tests were 
performed with the subjects seated and wearing 
a nose clip and a disposable mouthpiece. Only 
the expiratory phase was recorded.
Disease severity, on the basis of pulmonary 
function data, was classified in accordance with 
the Global Initiative for Chronic Obstructive Lung 
Disease criteria.(10)
In order to identify diagnoses of COPD, the 
same three questions used in the initial phase of 
the PLATINO study were used: “Has your doctor 
ever told you that you have emphysema in the 
lungs?”; “Has your doctor ever told you that 
you have chronic bronchitis?”, “Has your doctor 
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groups in terms of anthropometric characteristics 
or exposure to COPD risk factors (Tables 2 and 4); 
however, the subjects who went undiagnosed had 
better pulmonary function, less severe disease, 
and fewer symptoms of phlegm and wheeze, 
as well as a higher proportion of one or none 
self-reported symptom.
Discussion
The findings of the follow-up phase of the 
PLATINO study in the city of São Paulo, Brazil, 
show that approximately two thirds of the new 
COPD cases and of all COPD cases diagnosed 
until the end of the nine-year follow-up period 
had not received a prior diagnosis of COPD, and 
that these subjects have a clinical profile with 
fewer respiratory symptoms, better pulmonary 
function, and less severe disease as compared 
with those previously diagnosed with COPD.
It has been predicted that COPD will be the 
third leading cause of death in the world by 2020,(11) 
and, despite the significant socioeconomic impact 
of this disease, the underdiagnosis rates remain 
high. In the present study, the underdiagnosis rate 
was 70.0% for new COPD cases diagnosed until 
the end of the nine-year follow-up period and 
by using an FEV1/FVC ratio < 0.7 as the diagnostic 
criterion, are shown in Table 2. There was a 
17.5% reduction in the underdiagnosis rate, 
with a consequent increase in the proportion 
of subjects with a prior diagnosis of COPD for 
incident cases as compared with prevalent cases.
The characteristics of the subjects who went 
undiagnosed until the end of the follow-up phase 
of the study were also evaluated. We describe 
the anthropometric and clinical characteristics 
of the subjects who went undiagnosed and of 
those with a prior diagnosis of COPD during the 
follow-up phase of the PLATINO study (Table 3), 
as well as their history of exposure to COPD risk 
factors (Table 4). It can be seen that there were no 
statistically significant differences between these 
1,000 eligible subjects
56 nonlocated subjects
(5.6%)
944 located subjects 
(94.4%)
613 interviews performed 
(61.3%)
135 deaths
(13.5%)
141 declinations to 
participate (14.1%)
55 losses to follow-up 
(5.5%)
Participation rate 
(74.8%)
10 declinations to participate
6 unable subjects
2 out-of-state moves
1 exclusion
594 spirometric tests 
performed (96.9%)
Table 1 - Rates of underdiagnosis and prior diagnosis 
of COPD in new (incident) COPD cases and in all 
COPD cases during the follow-up phase of the study 
designated Latin-American Pulmonary Obstruction 
Investigation Project in the city of São Paulo, Brazil.a
Rate New cases All cases
(n = 20) (n = 53)
Underdiagnosis 14 (70.0) 33(62.3)
Prior diagnosis 6 (30.0) 20 (37.7)
aValues expressed as n (%).
Figure 1 - Flowchart of the follow-up phase of the study designated Latin-American Pulmonary Obstruction 
Investigation Project in the city of São Paulo, Brazil. 
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Table 3 - Anthropometric and clinical characteristics of the subjects who went undiagnosed and of those with 
a prior diagnosis of COPD during the follow-up phase of the study designated Latin-American Pulmonary 
Obstruction Investigation Project in the city of São Paulo, Brazil.a
Characteristic Undiagnosed With a prior diagnosis p
(n = 33) (n = 20)
Male gender 17 (53.1) 13 (65.0) 0.39
Age, yearsb 67.2 ± 10.3 67.7± 10.3 0.87
Level of education, yearsb 3.9± 4.4 4.2 ± 3.6 0.76
BMI,b kg/m2 26.5 ± 6.4 26.7 ± 7.9 0.95
Pulmonary functionb
Post-BD FEV1, L 1.84 ± 0.6 1.45 ± 0.7 0.04
Post-BD FEV1, % predicted 75.7 ± 20.7 58.5 ± 20.6 0.005
Post-BD FVC, L 2.82 ± 0.83 2.46 ± 1.1 0.18
Post BD FVC, % predicted 87.0 ± 21.6 73.1 ± 20.4 0.026
Post-BD FEV1/FVC 0.64 ± 0.05 0.58 ± 0.10 0.02
GOLD classification
1 (mild; FEV1 ≥ 80% predicted) 12 (37.5) 4 (5.0) 0.028
2 (moderate; 50 ≤ FEV1 < 80% predicted) 17 (53.1) 8 (40.0)
3/4 (severe/very severe; FEV1 < 50% predicted) 3 (9.4) 8 (40.0)
Quality of life questionnaireb
Physical domain 46.3 ± 10.5 40.2 ± 13.0 0.07
Mental domain 51.4 ± 11.0 48.0 ± 10.9 0.27
Presence of symptoms
Cough 11 (33.3) 11 (55.0) 0.12
Phlegm 9 (27.3) 13 (65.0) 0.007
Wheeze 13 (39.4) 15 (75.0) 0.01
Dyspnea 17 (53.1) 14 (73.7) 0.14
Grouped symptoms
None 7 (21.8) 1 (5.3) 0.021
1 10 (31.3) 2 (10.5)
2 9 (28.1) 5 (26.3)
> 2 6 (18.8) 11 (57.9)
BMI: body mass index; post-BD: post-bronchodilator; and GOLD: Global Initiative for Chronic Obstructive Lung Disease. 
aValues expressed as n (%). bValues expressed as mean ± SD
Table 2 - Rates of underdiagnosis and prior diagnosis 
of COPD in prevalent COPD cases during the initial 
phase of the study designated Projeto Latino-Americano 
de Investigação em Obstrução Pulmonar (PLATINO, 
Latin-American Pulmonary Obstruction Investigation 
Project) and in incident COPD cases during the follow-up 
phase of the PLATINO study, on the basis of the use 
of a post-bronchodilator FEV1/FVC ratio < 0.7 as the 
diagnostic criterion.a
Rate (Prevalent) 
COPD cases
New (incident) 
COPD cases
Underdiagnosis 126 (87.5) 14 (70.0)
Prior diagnosis 18 (12.5) 6 (30.0)
aValues expressed as n (%).
62.3% for all of the participants in the follow-up 
phase of the PLATINO study. Similar rates have 
been reported in a study involving primary health 
care clinics in the city of Aparecida de Goiânia, 
Brazil,(12) and in cross-sectional epidemiological 
studies conducted in other countries, such as 
Spain(13) and the USA,(14)—71.4%, 78.2%, and 74.9%, 
respectively—which shows that underdiagnosing 
COPD is not a problem observed only in developing 
countries. This means that spirometry is underused, 
a finding that has also been reported in a study 
conducted in Spain.(15) Such a finding underscores 
the need for raising awareness of the importance 
of spirometry and for expanding its use in primary 
health care clinics, since spirometry is the best 
way to increase the detection of COPD,(16) which 
prevents underdiagnosis of this disease. In addition, 
the adoption of simple and reasonable measures 
for use in interpreting spirometry can assist the 
health professional to use it to diagnose subjects, 
so that they can be properly treated.
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Previous epidemiological studies(5,6,17) and 
studies conducted in primary health care clinics(18,19) 
have reported these same characteristics in subjects 
who went undiagnosed. This shows that, even at 
the end of the nine-year follow-up period, the 
subjects who went undiagnosed had the same 
clinical profile, and the fact that they had few 
symptoms draws attention to the need for health 
professionals to use spirometry for diagnosis. 
It is of note that approximately 90% of the 
cases that went undiagnosed in the present 
study, considering the new COPD cases, had 
mild to moderate disease, showing that most of 
the subjects who went undiagnosed are in the 
initial stages of the disease, which makes early 
intervention possible.
One of the limitations of the present study is 
the rate of loss to follow-up, which exceeded 20%. 
However, a European multicenter longitudinal 
study over a similar follow-up period reported 
a participation rate of 63.3%.(20) In addition, 
the group consisting of losses to follow-up and 
declinations to participate had the same clinical 
and pulmonary function characteristics as those 
of the participants in the follow-up phase of the 
PLATINO study. Another limitation might be due 
to the fact that the diagnosis of COPD was based 
on the Global Initiative for Chronic Obstructive 
Lung Disease criterion (FEV1/FVC < 0.7), because 
However, a comparison of the underdiagnosis 
rate in new COPD cases during the follow-up phase 
of the PLATINO study with the underdiagnosis 
rate in prevalent COPD cases during the initial 
phase of the PLATINO study showed that there 
was a 17.5% reduction (70% in incident cases vs. 
87.5% in prevalent cases), with the proportion 
of diagnoses doubling (30.0% in incident cases 
vs. 12.5% in prevalent cases). It is very likely that 
the larger number of current diagnoses is due 
to the increased dissemination of information 
on the disease by the media, as a result of the 
efforts of the medical society. In addition, since 
we made our facility available to the subjects who 
had abnormal pulmonary function test results 
in the initial phase of the PLATINO study for 
consultation with a pulmonologist, this might 
also have contributed to the reduction in the 
underdiagnosis rate. However, special efforts 
should be made so that subjects with COPD can 
be diagnosed, and, therefore, the costs and impact 
of this disease on patients can be minimized.
The subjects who went undiagnosed until 
the end of the follow-up phase of the PLATINO 
study in the city of São Paulo, Brazil, had fewer 
respiratory symptoms, better pulmonary function, 
and less severe disease than did those previously 
diagnosed with COPD.
Table 4 - Characteristics of the subjects who went undiagnosed and of those with a prior diagnosis of COPD 
during the follow-up phase of the study designated Latin-American Pulmonary Obstruction Investigation 
Project in the city of São Paulo, Brazil, by exposure to COPD risk factors.a
Characteristic Undiagnosed With a prior diagnosis p
(n = 33) (n = 20)
Exposure to burning wood
Yes 24 (72.7) 15 (75.0) 0.94
No 9 (27.3) 5 (25.0)
Exposure to burning charcoal
Yes 8 (24.2) 5 (25.0) 0.86
No 25 (75.8) 15 (75.0)
Exposure to dust
Yes 22 (66.7) 17 (89.5) 0.07
No 11 (33.3) 2 (10.5)
History of respiratory infections in childhood
Yes 1 (3.0) 0 (0.0) 0.44
No 32 (97.0) 20 (100.0)
Smoking
Never smokers 11 (33.3) 6 (30.0) 0.89
Former smoker 14 (42.4) 8 (40.0)
Smoker 8 (24.2) 6 (30.0)
aValues expressed as n (%).
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sample of United States adults. Am J Respir Crit Care 
Med. 2001;164(3):372-7. http://dx.doi.org/10.1164/
ajrccm.164.3.2004029 PMid:11500335
15. Miravitlles M, de la Roza C, Morera J, Montemayor T, 
Gobartt E, Martín A, et al. Chronic respiratory symptoms, 
the use of this criterion can increase the rates 
of false-positive results in older subjects and 
might not detect the disease in younger subjects 
(false-positive results)(21); therefore, the use of 
the lower limit of normality is recommended by 
some authors.(22,23) It has recently been suggested 
that in disputed cases of airflow obstruction; 
i.e., cases with an FEV1/FVC ratio < 0.7 and an 
FEV1/FVC ≥ the lower limit of normality, subjects 
would not have clinically significant obstruction 
but would have a clinical profile characterized 
by important comorbidities, indicating that they 
could be at risk of developing COPD and should, 
therefore, be carefully followed.(24) However, 
the best criterion for the diagnosis of airflow 
obstruction remains in dispute in the literature,(25,26) 
and will continue so, since a recent longitudinal 
epidemiological study(27) has suggested the use 
of FEV1/FEV6 as a criterion, because FVC varies 
with expiratory time during forced maneuvers 
required for spirometry.
We conclude that the underdiagnosis rate in 
new COPD cases identified during the follow-up 
phase of the PLATINO study in the city of São 
Paulo, Brazil, was 70.0%. There was a 17.5% 
reduction in the underdiagnosis rate when we 
compared incident cases (follow-up phase of the 
PLATINO study) with prevalent cases (initial phase 
of the PLATINO study), and, even at the end of 
the nine-year follow-up period, the subjects who 
went undiagnosed continued to have the same 
clinical profile (better pulmonary function, less 
severe disease, and fewer symptoms).
The underdiagnosis rate of COPD identified in 
this population-based longitudinal epidemiological 
study was high, underscoring the need for raising 
awareness and expanding the use of spirometry 
in primary health care clinics.
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